No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxcarbazepine is rapidly reduced by cytosolic arylketone reductases to its active metabolite, 10-hydroxycarbazepine. No interaction is expected with emtricitabine, but oxcarbazepine might induce P-gp and therefore could reduce the absorption of tenofovir-DF. However, based on the results of the interaction study between tenofovir-DF and rifampicin (another inducer of P-gp), oxcarbazepine would be expected to cause only a small decrease in tenofovir-DF.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking